Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Albacete – page 4

61 clinical trials in Albacete, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Albacete at a glance
61
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

61 trials in Albacete

Open in trial search

Infertility female

Not yet recruiting

Study of testosterone gel treatment for women with low ovarian reserve and androgen receptor polymorphism undergoing fertility treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Instituto Bernabeu S.L.

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Post-acute COVID-19 syndrome+1

Not recruiting

Study on the Effects and Safety of Ginkgo Biloba Extract in Patients with Cognitive Impairment After COVID-19

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:REFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED TO 22.0 TO 27.0 % OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2.8 TO 3.4 % OF GINKGOLIDES A, B AND C, AND 2.6 TO 3.2 % OF BILOBALIDE. EXTRACTION SOLVENT: ACETONE 60% (M/M)
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Acute myeloid leukaemia

Not recruiting

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Huntington's disease

Not recruiting

Study on the Effects of Metformin on Cognitive Function in Patients with Huntington's Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Hydrochloride
  • Sponsor:IIS La Fe

Vitamin D deficiency

Not recruiting

Study on the Effectiveness of Cholecalciferol and Calcifediol in Treating Severe Vitamin D Deficiency in Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcifediol
  • Sponsor:Itf Research Pharma S.L.

Cardiac failure chronic+1

Not recruiting

Study on Managing Heart Failure and Kidney Disease in Elderly Patients with High Potassium Risk Using Sodium Zirconium Cyclosilicate

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:Hospital Clinico Universitario De Valencia

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Transitional cell carcinoma

Not recruiting

Study of Atezolizumab Treatment Before Surgery in Patients with Bladder Cancer or Upper Urinary Tract Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Queen Mary University Of London

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Albacete

What the registry says about research in the country

01 Neurological Conditions

Clinical trials focusing on acute ischemic stroke treatments and innovative therapies for multiple sclerosis. Research includes evaluation of novel compounds like sovateltide and studies on cognitive function in Huntington's Disease.

  • Stroke treatment optimization
  • Neurodegenerative diseases
  • Post-COVID cognitive impairment

Studies aim to improve patient outcomes and enhance neurological function recovery.

02 Oncology Research

Comprehensive studies on various cancer types, including breast cancer treatments and acute myeloid leukemia. Research focuses on targeted therapies and novel drug combinations.

  • Triple-negative breast cancer
  • Leukemia treatments
  • Immunotherapy approaches

Investigations aim to improve survival rates and treatment effectiveness.

03 Cardiovascular Studies

Research on coronary artery conditions and treatment strategies for various cardiac disorders. Studies include evaluation of antiplatelet agents and innovative approaches to pulmonary embolism.

  • Arterial dissection treatments
  • Platelet inhibition strategies
  • Heart failure management

Focus on improving cardiac care outcomes and patient safety.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.